Anti-MET Antibody Therapies in Non-Small-Cell Lung Cancer: Current Progress and Future Directions

Anti-MET Antibody Therapies in Non-Small-Cell Lung Cancer: Current Progress and Future Directions

<b>Background/Objectives:</b> Non-small-cell lung cancer (NSCLC) remains a leading cause of cancer mortality globally, though advances in targeted therapies have improved treatment outcomes. The mesenchymal–epithelial transition (<i>MET</i>) gene plays a significant role in N...

Full description

Saved in:

Bibliographic Details
Main Authors:	Kinsley Wang, Robert Hsu
Format:	Article
Language:	English
Published:	MDPI AG 2024-10-01
Series:	Antibodies
Subjects:	MET (mesenchymal–epithelial transition factor) NSCLC (non-small-cell lung cancer) EGFR-mutated NSCLC targeted therapies amivantamab
Online Access:	https://www.mdpi.com/2073-4468/13/4/88
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Amivantamab versus standard therapies among patients with advanced non-small cell lung cancer and epidermal growth factor receptor exon 20 insertion mutations after platinum-based therapy in China
by: Lan Shen, et al.
Published: (2025-08-01)

Combination Therapy With MET Tyrosine Kinase Inhibitor and EGFR Tyrosine Kinase Inhibitor in Patients With MET-Overexpressed EGFR-Mutant Lung Adenocarcinoma
by: Jia-Jun Wu, MD, et al.
Published: (2025-06-01)

Review of real-world studies on capmatinib use in MET-mutated lung cancer
by: A. A. Kurylev, et al.
Published: (2025-04-01)

Ensartinib for advanced or metastatic non-small-cell lung cancer with MET exon 14 skipping mutations (EMBRACE): a multi-center, single-arm, phase 2 trialResearch in context
by: Yang Xia, et al.
Published: (2025-03-01)

Recent advances in the treatment of non-small cell lung cancer with MET inhibitors
by: Dongna Zhang, et al.
Published: (2024-12-01)

Differential Responses to Targeted Therapies in Non-Small Cell Lung Cancer: A Comparative Analysis of Outcomes in Patients with Single EGFR Mutation and Concurrent Gene Alterations
by: Le LT, et al.
Published: (2025-07-01)

Expert consensus on the diagnosis and treatment of non-small cell lung cancer with MET alteration
by: Huijing Feng, et al.
Published: (2025-03-01)

Lung Adenocarcinoma With Initially Co‐Occurring EGFR and BRAF Double Mutation: A Case Report and Literature Review
by: Lu Wang, et al.
Published: (2025-03-01)

Discovery of LAH-1 as potent c-Met inhibitor for the treatment of non-small cell lung cancer
by: Lijie Sima, et al.
Published: (2024-12-01)

New therapeutic approaches for EGFR mutated non-small cell lung cancer on osimertinib era
by: Jaime Rubio-Perez, et al.
Published: (2025-01-01)

Real-world pharmacovigilance analysis unveils the toxicity profile of amivantamab targeting EGFR exon 20 insertion mutations in non-small cell lung cancer
by: Jing Zhang, et al.
Published: (2025-02-01)

Fexofenadine Overcomes Osimertinib Resistance by Inhibiting c‐Met in Non‐Small Cell Lung Cancer
by: Kenneth K. W. To, et al.
Published: (2025-06-01)

Review of Plasma Exosomal DNA for Detecting EGFR Mutations in Non-Small Cell Lung Cancer (NSCLC)
by: Mohammad Mehdi Jahani, et al.
Published: (2025-04-01)

City scale related to epidermal growth factor receptor mutations status in Chinese non-small cell lung cancer
by: Guang-Gui Ding, et al.
Published: (2025-05-01)

A Case Report of Lung Adenocarcinoma with EGFR G719A Mutation  and LMNA-NTRK1 Fusion
by: Shiqi SONG, et al.
Published: (2025-01-01)

Current Status and Future Prospects of Treatment for EGFR-Positive Non-Small Cell Lung Cancer After Resistance to EGFR-TKI
by: Yiming ZENG, et al.
Published: (2025-06-01)

Early-stage resectable non-small cell lung cancer in Hungary
by: Gabriella Gálffy, et al.
Published: (2025-07-01)

MET exon 14 skipping mutations in non-small-cell lung cancer a 3 years screening experience
by: R. Ben Dhiab, et al.
Published: (2025-06-01)

The correlation of HLA-A in Thai EGFR-mutated advanced non-small cell lung cancer, outcome, and tumor microenvironment
by: Nicha Zungsontiporn, et al.
Published: (2025-08-01)

Role of TP53 Mutations and EGFR Amplification in Risk Stratification of Early‐Stage EGFR‐Mutated Non‐Small Cell Lung Cancer With Immunohistochemistry as a Surrogate Marker
by: Meejeong Kim, et al.
Published: (2025-04-01)

Comparative Survival Analysis of Anti‐Angiogenic Agent Plus Immunochemotherapy in NSCLC Patients After Frontline EGFR‐TKI Treatment: A Retrospective Cohort Study
by: Yi‐Tse Su, et al.
Published: (2025-07-01)

A CMTM6 Nanobody Overcomes EGFR‐TKI Resistance in Non‐Small Cell Lung Cancer
by: Lu Xia, et al.
Published: (2025-07-01)

TRANS: a prediction model for EGFR mutation status in NSCLC based on radiomics and clinical features
by: Zhigang Chen, et al.
Published: (2025-06-01)

Clinical Management in NSCLC Patients With EGFR Mutation After Osimertinib Progression With Unknown Resistance Mechanisms
by: Xin Liao, et al.
Published: (2024-10-01)

Airway microbiota associated D-phenylalanine promotes non-small cell lung cancer metastasis through epithelial mesenchymal transition
by: Lin Gao, et al.
Published: (2025-06-01)

Non‐canonical cMet regulation by vimentin mediates Plk1 inhibitor–induced apoptosis
by: Ratnakar Singh, et al.
Published: (2019-04-01)

A Novel Exon 19 EGFR mutation in a patient with lung adenocarcinoma: A Case Report and Literature Review
by: Laura Gutiérrez-Sainz, et al.
Published: (2025-06-01)

A trispecific antibody targeting EGFR/cMET/VEGF-A demonstrates multiple mechanisms of action to inhibit wild-type and mutant NSCLC animal models
by: Ying Jin, et al.
Published: (2025-05-01)

Molecular characteristics and responses to EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients with EGFR exon 19 insertions
by: Yang Li, et al.
Published: (2025-04-01)

Concomitant ALK Fusion and TP53/EGFR Mutation Lead to Adverse Prognostic Outcome
by: Mingyuan Du, et al.
Published: (2024-12-01)

Traditional Chinese Medicines as Anticancer Agents for Non-Small Cell Lung Cancer with EGFR Mutations: A Review
by: Wang Z, et al.
Published: (2025-06-01)

Concomitant Use of Analgesics and EGFR TKIs in Lung Cancer Patients: Outcomes and Perspectives From a Finnish Retrospective Register–Based Study
by: Laura S. Puuniemi, et al.
Published: (2025-07-01)

Radiation-Induced Tumor-Derived Extracellular Vesicles Combined with Tyrosine Kinase Inhibitors: An Effective and Safe Therapeutic Approach for Lung Adenocarcinoma with EGFR19Del
by: Yao Li, et al.
Published: (2024-12-01)

Discovery of novel thiazolyl-pyrazolines as dual EGFR and VEGFR-2 inhibitors endowed with in vitro antitumor activity towards non-small lung cancer
by: Esraa A. Abdelsalam, et al.
Published: (2022-12-01)

OPTIMAL SEQUENCE OF APPLICATION OF EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS IN ADVANCED NON-SMALL CELL LUNG CANCER PATIENTS WITH ACTIVATING EGFR MUTATIONS
by: A. A. Kolomeytseva, et al.
Published: (2020-12-01)

Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non‐small cell lung cancer
by: Azhar Ali, et al.
Published: (2018-02-01)

Immunological features of EGFR-mutant non-small cell lung cancer and clinical practice: a narrative review
by: Yi Dong, et al.
Published: (2024-12-01)

Case Report: Grade 4 pneumonitis occurred after thoracic radiotherapy and dacomitinib in a patient with lung adenocarcinoma
by: Ailing Liu, et al.
Published: (2025-02-01)

Impact of Subsequent Treatment on Clinical Outcomes in Patients with EGFR-Mutant Non-Small Cell Lung Cancer Transformed to Small-Cell Lung Cancer
by: Chen CY, et al.
Published: (2025-04-01)

Tumor-associated macrophages derived exosomal circPLK1 promotes resistance to EGFR inhibitor osimertinib in non-small cell lung cancer
by: Chuankui Li, et al.
Published: (2025-07-01)